Mucopolysaccharidosis Type IIIA
Rare Disease·MeSH: Mucopolysaccharidosis III
Prevalence
5.0 / 100K
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| otl-201 | Orchard Therapeutics plc (ORTX) |
Phase 2(1)
| Drug | Company |
|---|---|
| DNL126 | Denali Therapeutics Inc. (DNLI) |
Compare drugs
Frequently asked questions
How many drugs are in development for Mucopolysaccharidosis Type IIIA?
BioSniper tracks 2 drugs in development for Mucopolysaccharidosis Type IIIA across 2 companies.
How many clinical trials target Mucopolysaccharidosis Type IIIA?
There are 1 clinical trial targeting Mucopolysaccharidosis Type IIIA tracked by BioSniper.
What is the prevalence of Mucopolysaccharidosis Type IIIA?
The estimated prevalence of Mucopolysaccharidosis Type IIIA is approximately 5.0 per 100,000 population.
Deep-dive into Mucopolysaccharidosis Type IIIA
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis